Insmed financials
$115.63−1.73%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $425.5M | $306.0M | $263.8M | $142.3M | $107.4M | $92.8M | $104.4M | $93.4M | $90.3M | $75.5M | $83.7M | $79.1M |
| Gross profit | $358.3M | $258.5M | $219.6M | $113.0M | $79.3M | $71.5M | $78.3M | $72.3M | $69.4M | $58.0M | $65.3M | $62.4M |
| Gross margin | 84.2% | 84.5% | 83.2% | 79.4% | 73.9% | 77.1% | 75.0% | 77.3% | 76.8% | 76.9% | 78.0% | 78.9% |
| Operating income | -$1.5M | -$153.3M | -$319.7M | -$366.0M | -$312.9M | -$248.1M | -$230.4M | -$213.4M | -$288.9M | -$145.5M | -$178.3M | -$147.7M |
| Net income | -$13.2M | -$163.6M | -$328.5M | -$370.0M | -$321.7M | -$256.6M | -$235.5M | -$220.5M | -$300.6M | -$157.1M | -$186.1M | -$158.9M |
| Net margin | −3.1% | −53.5% | −124.5% | −260.0% | −299.5% | −276.4% | −225.5% | −236.0% | −332.8% | −208.1% | −222.3% | −201.0% |
| Diluted EPS | $-0.06 | $-0.76 | $-1.53 | $-1.75 | $-1.70 | $-1.42 | $-1.31 | $-1.27 | $-1.94 | $-1.06 | $-1.28 | $-1.11 |
| EBITDA | $3.7M | -$148.3M | -$314.2M | -$362.0M | -$309.1M | -$245.0M | -$227.7M | -$210.7M | -$286.9M | -$153.9M | -$162.6M | -$135.2M |
| Operating cash flow | -$88.8M | -$222.7M | -$247.6M | -$219.8M | -$205.6M | -$262.1M | -$196.0M | -$180.9M | -$134.9M | -$172.1M | -$130.8M | -$136.3M |
| Free cash flow | -$95.1M | -$226.2M | -$264.2M | -$222.2M | -$209.1M | -$272.2M | -$202.8M | -$184.6M | -$141.6M | -$176.8M | -$133.0M | -$139.2M |
| Diluted shares | 217.4M | 215.5M | 214.1M | 211.8M | 189.3M | 180.9M | 179.3M | 173.7M | 154.7M | 148.5M | 144.9M | 142.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $544.8M | $582.2M | $510.4M | $334.8M | $1.28B | $403.2M |
| Short-term investments | $615.5M | $641.3M | $919.6M | $1.35B | $572.4M | $796.2M |
| Total debt | $566.0M | $565.5M | $565.0M | $564.6M | $564.1M | $1.13B |
| Total assets | $2.10B | $2.08B | $2.26B | $2.36B | $2.48B | $1.80B |
| Total liabilities | $1.35B | $1.37B | $1.53B | $1.42B | $1.23B | $1.70B |
| Shareholders' equity | $757.5M | $704.9M | $739.0M | $945.6M | $1.25B | $99.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology